ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE

Clinical trials for ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE explained in plain language.

Never miss a new study

Get alerted when new ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE trials appear

Sign up with your email to follow new studies for ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Repurposed leukemia drug tested for Tough-to-Treat lung cancer

Disease control Recruiting now

This early-phase study is testing the safety and tolerability of gilteritinib, a drug already approved for a type of leukemia, in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) whose cancer has stopped responding to prior ALK inhibitor treatments. About 40 p…

Matched conditions: ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE

Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE

Get alerted when new ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE trials appear

Repurposed leukemia drug tested for Tough-to-Treat lung cancer